ANDA 216119, held by Jiangsu Hansoh Pharm. Dapagliflozin.
As of Nov 15, 2026, ANDA 216119 (Dapagliflozin), held by Jiangsu Hansoh Pharm, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 2, 2026 | Original application | Tentative approval | None posted |
| Dapagliflozin5MG · tablet;oral | Dapagliflozin | None (tentative approval) |
| Dapagliflozin10MG · tablet;oral | Dapagliflozin | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters